ESTRO 2025 - Abstract Book

S1917

Clinical - Urology

ESTRO 2025

Conclusion: Neurovascular-sparing EBRT with 36.25 Gy in 5 fractions using an MR-Linac results in a reduced incidence of ED and preserved erectile function up to 18 months compared to conventional radiotherapy treatment. Final ED data and oncological outcomes will be reported upon completion of this trial (36 months post-treatment) in June 2026.

Keywords: MRgRT, quality of life, erectile dysfunction

References: 1. Teunissen FR, van der Voort van Zyp JRN, Verkooijen HM, Wortel RC. Neurovascular-Sparing MR-Guided Adaptive Radiotherapy in Prostate Cancer; Defining the Potential Population for Erectile Function-Sparing Treatment. J Sex Med [Internet]. 2022 Jul 1;19(7):1196 – 200.